{"id":2601,"date":"2018-03-22T18:00:13","date_gmt":"2018-03-22T12:30:13","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2601"},"modified":"2024-09-17T15:46:36","modified_gmt":"2024-09-17T10:16:36","slug":"business-cocktail-latest-pharma-news-3","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion<\/strong><\/p>\n<p style=\"text-align: justify;\">Two major pharmaceutical companies (Merck &amp; Eisai) has entered into a <strong>USD 5.76 Billion<\/strong> pact to develop and commercialize Lenvima (lenvatinib mesylate) both as a monotherapy and an in-combination therapy for treating multiple types of cancer. The drug will be used in combination with Keytruda (pembrolizumab), Merck\u2019s blockbuster drug with a recorded<strong> USD 3.8 Billion<\/strong> sales in 2017.<\/p>\n<p style=\"text-align: justify;\"><strong>Lundbeck planning to buy Prexton therapeutics for its phase 2 Parkinson\u2019s drug<\/strong><\/p>\n<p style=\"text-align: justify;\">In a recent deal Lundbeck is&nbsp;paying&nbsp;<strong>USD 123 Million<\/strong> up front to buy Prexton Therapeutics and its phase 2 Parkinson\u2019s disease drug. With this deal Lundbeck will hold control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents. Lundbeck is handing over <strong>USD 123 Million<\/strong> upfront and committing to pay up to<strong> USD 992 Million<\/strong> in milestones tied to clinical, regulatory and commercial successes.<\/p>\n<p style=\"text-align: justify;\"><strong>Sun Pharma has recently announced USFDA approval of ILUMYA for the treatment of Moderate-to-Severe Plaque Psoriasis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Sun Pharma<\/strong> has recently announced that USFDA has approved <strong>ILUMYA<\/strong> for the treatment of adults with moderate-to-severe plaque psoriasis. ILUMYA specifically binds to the p19 subunit of IL-23 and inhibits its interaction with IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines.<\/p>\n<p style=\"text-align: justify;\"><strong>Ocugen moving to Phase 3 with dry eye disease drug <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Ocugen Biotherapeutics<\/strong>, an eye disease specialist company is moving ahead with its drug candidates after getting FDA approval for its dry eye drug candidate <strong>OCU310<\/strong>. Company has recently cleared a phase 2 trial for OCU310 and is now moving into phase 3 trial. The results has shown that OCU310 a combination of already-approved drugs <strong>brimonidine tartrate<\/strong> and <strong>loteprednol etabonate<\/strong> has successfully improved&nbsp;various symptoms of dry eye disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck &amp; Eisai) has entered into a USD 5.76 Billion pact to develop and commercialize Lenvima (lenvatinib mesylate) both as a monotherapy and an in-combination therapy for treating multiple types of cancer. The drug will be [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1550,204,1541,1547,345,1543,1542,1549,1544,395,1548,1551,450,905,1230,1261,1546,1545,802,595],"industry":[17225],"therapeutic_areas":[17227,17245,17228,17244],"class_list":["post-2601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-brimonidine-tartrate","tag-delveinsight","tag-eisai","tag-ilumya","tag-keytruda","tag-lenvatinib-mesylate","tag-lenvima","tag-loteprednol-etabonate","tag-lundbeck","tag-merck","tag-ocu310","tag-ocugen-biotherapeutics","tag-parkinsons","tag-pembrolizumab","tag-pharma-consultancy","tag-pharma-consulting","tag-plaque-psoriasis","tag-prexton-therapeutics","tag-sun-pharma","tag-usfda","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Merck, Eisai, Lundbeck, Sun Pharma<\/title>\n<meta name=\"description\" content=\"Sun Pharma has recently announced that USFDA has approved ILUMYA for the treatment of adults with moderate-to-severe plaque psoriasis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Merck, Eisai, Lundbeck, Sun Pharma\" \/>\n<meta property=\"og:description\" content=\"Sun Pharma has recently announced that USFDA has approved ILUMYA for the treatment of adults with moderate-to-severe plaque psoriasis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-22T12:30:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:16:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2450\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Merck, Eisai, Lundbeck, Sun Pharma","description":"Sun Pharma has recently announced that USFDA has approved ILUMYA for the treatment of adults with moderate-to-severe plaque psoriasis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Merck, Eisai, Lundbeck, Sun Pharma","og_description":"Sun Pharma has recently announced that USFDA has approved ILUMYA for the treatment of adults with moderate-to-severe plaque psoriasis.","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-03-22T12:30:13+00:00","article_modified_time":"2024-09-17T10:16:36+00:00","og_image":[{"width":2450,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3","name":"Pharma News | Merck, Eisai, Lundbeck, Sun Pharma","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","datePublished":"2018-03-22T12:30:13+00:00","dateModified":"2024-09-17T10:16:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Sun Pharma has recently announced that USFDA has approved ILUMYA for the treatment of adults with moderate-to-severe plaque psoriasis.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-3#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","width":2450,"height":1080,"caption":"News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">brimonidine tartrate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eisai<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ILUMYA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">lenvatinib mesylate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lenvima<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">loteprednol etabonate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lundbeck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">OCU310<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ocugen Biotherapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pembrolizumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plaque Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prexton therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sun Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USFDA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">brimonidine tartrate<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Eisai<\/span>","<span class=\"advgb-post-tax-term\">ILUMYA<\/span>","<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">lenvatinib mesylate<\/span>","<span class=\"advgb-post-tax-term\">Lenvima<\/span>","<span class=\"advgb-post-tax-term\">loteprednol etabonate<\/span>","<span class=\"advgb-post-tax-term\">Lundbeck<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">OCU310<\/span>","<span class=\"advgb-post-tax-term\">Ocugen Biotherapeutics<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s<\/span>","<span class=\"advgb-post-tax-term\">Pembrolizumab<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Plaque Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">Prexton therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Sun Pharma<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Mar 22, 2018","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Mar 22, 2018 6:00 pm","modified":"Updated on Sep 17, 2024 3:46 pm"},"featured_img_caption":"News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2601"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2601\/revisions"}],"predecessor-version":[{"id":29541,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2601\/revisions\/29541"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2434"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2601"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2601"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}